ClinicalTrials.gg
RecruitingNCT06863155ACO_FLEXUpdated Aug 6, 2026

Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation

An observational study in Coronary Artery Disease and Ischemic Heart Disease, sponsored by Fundación EPIC. Recruiting at 13 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Fundación EPIC · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 33 studies in Coronary Artery Disease by Fundación EPIC — 13 open to participants now, 20 under way, none of them phase 3. Coronary Artery Disease · Fundación EPIC.

Planned enrollment
8th of 20
500 · median 375
Started
2025
with 4 others
Observational
20 of 33
5 open now
Primary completion
2027-03
later than 12 of 19 live
Registered
29th of 33
by date

Among the 33 studies in Coronary Artery Disease by Fundación EPIC, this one is the 8th largest by planned enrollment of the 20 observational ones that give a count, is one of 5 that started in 2025, is one of 20 observational ones, reaches primary completion later than 12 of the 19 other live ones, and was the 29th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

13 of the 33 studies in Coronary Artery Disease by Fundación EPIC are open now, in 7 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Coronary Artery Disease by Fundación EPIC, or all of them as a file.
02

Study summary

Patients receiving chronic oral anticoagulation with indication for percutaneous coronary revascularization with stent implantation, and needing for antiplatelet therapy, are at high risk of bleeding. The new generation of ultrathin strut sirolimus-eluting stent with bioabsorbable polymer allow for shorter antiplatelets regimens and could be a good option for this high-bleeding risk patients.

Read the detailed description

Patients receiving chronic oral anticoagulation with indication for percutaneous coronary revascularization with stent implantation, and needing for antiplatelet therapy, are at high risk of bleeding. The new generation of ultrathin strut sirolimus-eluting stent with bioabsorbable polymer allow for shorter antiplatelets regimens and could be a good option for this high-bleeding risk patients.

03

Conditions studied

  • Coronary Artery Disease
  • Ischemic Heart Disease

Keywords

  • Chronic oral anticoagulation
  • Ultrathin-strut stent
  • Biodegradable polymer
  • High-bleeding risk
  • Percutaneous Coronary Intervention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients under chronic oral anticoagulation undergoing PCI with implantation of a SupraFlex Cruz(r) stent

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all inclusion criteria:

  • Patients with Signed and
  • Patients with >=18 years old and
  • Patients with chronically receiving oral anticoagulation treatment with any type of anticoagulant for any reason and
  • Patients with de novo Coronary artery disease requiring both elective or urgent percutaneous revascularization due to stable coronary artery disease or acute coronary syndrome with or without ST-segment elevation, and in which an ultrathin strut Sirolimus-eluting stent with bioabsorbable polymer has been used

Exclusion criteria

Exclusion Criteria:

Patients do not have to meet any exclusion criteria

  • Patients treated percutaneously with any type of stent other than the SupraFlex Cruz® in the 6 months prior to the index procedure in which he or she is included.
  • Use in the same procedure or in a scheduled procedure of other stents different from the one evaluated for the treatment of another vessel(s).
  • Patients treatment for restenosis or stent thrombosis.
  • Patients presentation in cardiogenic shock or after cardiorespiratory arrest.
  • Patients with allergy to any of the components of the stent to be used.
  • Patients with impossibility for follow-up.
  • Patients with less than 1 year.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Supraflex Cruz Sirolimus-eluting Stent

    Device: Supraflex Cruz Sirolimus-eluting Stent

Interventions

  • DeviceSupraflex Cruz Sirolimus-eluting Stent

    PCI with SupraFlex Cruz® stent in de novo coronary stenosis of patients under chronic oral anticoagulation.

06

What researchers measure

Primary outcomes

  1. NACE (Net Adverse Clinical Events)

    Combined endpoint of Cardiac Death, Acute Myocardial Infarction, Stroke, Need for new Treated Vessel Revascularization (TVR) and BARC (Bleeding Academic Research Consortium) 3-5

    Time frame: 12 month

Secondary outcomes

  1. MACE (Major Adverse Cardiac Events)

    To assess the occurrence of major adverse cardiac events (MACE) in patients receiving chronic oral anticoagulation who have been treated with ultrathin strut Sirolimus-eluting stents with bioabsorbable polymer.

    Time frame: 12 months

  2. MACE (Major Adverse Cardiac Events)

    To assess the occurrence of major adverse cardiac events (MACE) in patients receiving chronic oral anticoagulation who have been treated with ultrathin strut Sirolimus-eluting stents with bioabsorbable polymer.

    Time frame: 6 months

  3. TLF (Target Lesion Failure)

    To assess the failure rate of the lesion treated (TLF) with ultrathin strut Sirolimus-eluting stent with bioabsorbable polymer in patients receiving chronic oral anticoagulation.

    Time frame: 12 months

  4. TLF (Target Lesion Failure)

    To assess the failure rate of the lesion treated (TLF) with ultrathin strut Sirolimus-eluting stent with bioabsorbable polymer in patients receiving chronic oral anticoagulation.

    Time frame: 6 months

  5. Death

    To assess the occurrence of Death

    Time frame: 12 months

  6. Death

    To assess the occurrence of Death

    Time frame: 6 months

  7. Acute Myocardial Infarction (AMI)

    To assess the occurrence of AMI

    Time frame: 12 months

  8. Acute Myocardial Infarction (AMI)

    To assess the occurrence of AMI

    Time frame: 6 months

  9. Stroke

    To assess the occurrence of Stroke

    Time frame: 12 months

  10. Stroke

    To assess the occurrence of Stroke

    Time frame: 6 months

  11. Target vessel revascularization (TVR)

    To assess the occurrence of TVR

    Time frame: 12 months

  12. Target vessel revascularization (TVR)

    To assess the occurrence of TVR

    Time frame: 6 months

07

Study locations

13 of 13 sites recruiting
  • Hospital General Universitario de Albacete
    Albacete, 02008, Spain
    Recruiting
  • Hospital Universitario San Juan de Alicante
    Alicante, 03550, Spain
    Recruiting
  • Hospital General Universitario de Merida
    Badajoz, 6800, Spain
    Recruiting
  • Hospital General Universitari de Castelló
    Castelló, 12004, Spain
    Recruiting
  • H.G.U. de Ciudad Real.
    Ciudad Real, 13005, Spain
    Recruiting
  • Hospital General Universitari d'Elx
    Elche, 03203, Spain
    Recruiting
  • Hospital Universitari de Bellvitge
    L'Hospitalet de Llobregat, 08907, Spain
    Recruiting
  • Hospital Universitario de Canarias
    Laguna, 38320, Spain
    Recruiting
  • Hospital Doctor Jose Molina Orosa
    Las Palmas de Gran Canaria, 35500, Spain
    Recruiting
  • Hospital Universitario Puerta de Hierro
    Majadahonda, 28222, Spain
    Recruiting
  • Hospital Universitario de Navarra
    Pamplona, 31008, Spain
    Recruiting
  • Hospital General de Fuerteventura
    Puerto del Rosario, 35600, Spain
    Recruiting
  • Hospital Clinico Universitario Lozano Blesa
    Zaragoza, 50009, Spain
    Recruiting
08

References and documents

Publications

  • Lemos PA, Chandwani P, Saxena S, Ramachandran PK, Abhyankar A, Campos CM, Marchini JF, Galon MZ, Verma P, Sandhu MS, Parikh N, Bhupali A, Jain S, Prajapati J. Clinical outcomes in 995 unselected real-world patients treated with an ultrathin biodegradable polymer-coated sirolimus-eluting stent: 12-month results from the FLEX Registry. BMJ Open. 2016 Feb 17;6(2):e010028. doi: 10.1136/bmjopen-2015-010028. PubMed 26888727 ↗
  • Choudhury A, Garg S, Smith J, Sharp A, Nabais de Araujo S, Chauhan A, Patel N, Wrigley B, Chattopadhyay S, Zaman AG. Prospective evaluation of an ultrathin strut biodegradable polymer-coated sirolimus-eluting stent: 12 months' results from the S-FLEX UK registry. BMJ Open. 2019 Oct 11;9(10):e026578. doi: 10.1136/bmjopen-2018-026578. PubMed 31604782 ↗
  • Zaman A, de Winter RJ, Kogame N, Chang CC, Modolo R, Spitzer E, Tonino P, Hofma S, Zurakowski A, Smits PC, Prokopczuk J, Moreno R, Choudhury A, Petrov I, Cequier A, Kukreja N, Hoye A, Iniguez A, Ungi I, Serra A, Gil RJ, Walsh S, Tonev G, Mathur A, Merkely B, Colombo A, Ijsselmuiden S, Soliman O, Kaul U, Onuma Y, Serruys PW; TALENT trial investigators. Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. Lancet. 2019 Mar 9;393(10175):987-997. doi: 10.1016/S0140-6736(18)32467-X. Epub 2019 Feb 28. PubMed 30827782 ↗
  • Biscaglia S, Guiducci V, Escaned J, Moreno R, Lanzilotti V, Santarelli A, Cerrato E, Sacchetta G, Jurado-Roman A, Menozzi A, Amat Santos I, Diez Gil JL, Ruozzi M, Barbierato M, Fileti L, Picchi A, Lodolini V, Biondi-Zoccai G, Maietti E, Pavasini R, Cimaglia P, Tumscitz C, Erriquez A, Penzo C, Colaiori I, Pignatelli G, Casella G, Iannopollo G, Menozzi M, Varbella F, Caretta G, Dudek D, Barbato E, Tebaldi M, Campo G; FIRE Trial Investigators. Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction. N Engl J Med. 2023 Sep 7;389(10):889-898. doi: 10.1056/NEJMoa2300468. Epub 2023 Aug 26. PubMed 37634150 ↗
  • Paradies V, Maurina M, Tonino P, Hofma SH, Vos J, van Kuijk JP, Oemrawsingh RM, Mafragi AA, Spano F, Pisters R, Polad J, Ijsselmuiden S, Cambero MM, Smits PC. Comparison of Supraflex Cruz 60 mum Versus Ultimaster Tansei 80 mum Stent Struts in High Bleeding Risk PCI Patients: Study design and Rational of Compare 60/80 HBR trial. Am J Cardiol. 2023 Nov 1;206:230-237. doi: 10.1016/j.amjcard.2023.08.046. Epub 2023 Sep 13. PubMed 37708755 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Mar 2027, 22 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 22 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2025
First posted
Mar 7, 2025
StartActual
May 6, 2025
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2029
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06863155
Lead sponsor
Fundación EPIC
Responsible party
Sponsor
First posted
Mar 7, 2025
Start date
May 6, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Aug 6, 2026

Study contacts

Juan Gabriel Córdoba Soriano, MD, PhD
Contact
jgcordoba@foroepic.org
0034 967597532
FUNDACION EPIC
Contact
iepic@fundacionepic.org
0034987876135

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion